Abstract
Esomeprazole {(S)-5-methoxy-2-[(4-methoxy-3, 5-dimethyl-2-pyridinylmethyl) sulfinyl]-1H-benzimidazole} is a proton pump inhibitor used as an antiulcer drug. Its R-enantiomer 3 was synthesized with high enantioselectivity by asymmetric oxidation of prochiral sulfide 2 using the oxaziridinium salt 4. Product 3, useful as a reference for the quality control of esomeprazole, was characterized by 1H and 13C NMR, IR, and HRMS. The enantiomeric excess was determined by HPLC.
Introduction
Safety and efficacy of pharmaceuticals are two fundamental issues of importance in drug therapy. The safety of a drug is determined by its pharmacological toxicological profile and the adverse effects caused by impurities. Therefore, the products intended for human consumption must be characterized completely. The quality and safety of a drug is generally assured by monitoring and controlling the impurities effectively. Esomeprazole (Figure 1) is a strong proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease and Zollinger-Ellison syndrome [1]. The drug suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cells. It was launched as Nexium® in 2000 by AstraZeneca to improve the pharmacokinetic profile and potency of the racemic product. Only the S-enantiomer shows high biological activity.

Chemical structure of esomeprazole (S-enantiomer).
The R-enantiomer differs in absolute stereochemistry around the sulfur atom.
Many synthetic routes [2–7] have been developed for the synthesis of esomeprazole in recent years. Impurities, including the R-enantiomer of esomeprazole, are generally formed during the synthesis. In order to enhance the safety of esomeprazole and effectively control drug quality, a facile preparation of the optically pure R-enantiomer of esomeprazole is desired. So far, several tedious methods [8–12] for the preparation of the R-enantiomer have been reported, including asymmetric synthesis and enantiomeric separation. In this report, we describe a facile synthetic approach to the R-enantiomer of esomeprazole.
Results and discussion
Our efficient approach is based on the work of Del Rio [13] of highly enantioselective asymmetric oxidation of prochiral sulfides using the oxaziridinium salt 4.
As shown in Scheme 1, treatment of 5-methoxybenzimidazol-2(1H)-thione (1) with 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride gave the sulfanyl derivative 2 in a 95% yield [14, 15]. The highly enantioselective oxidation reaction of 2 by the oxaziridinium salt 4 proceeded smoothly in dichloromethane and furnished the desired product 3 with excellent enantioselectivity (98% ee). The chemical yield was 86%. The structure was fully supported by analysis of 1H NMR, 13C NMR, IR, and HRMS data.

Asymmetric synthesis of the R-enantiomer of esomeprazole.
Conclusion
A highly enantioselective synthesis of the R-enantiomer of esomeprazole has been developed using oxidation of prochiral sulfide 2 with the asymmetric oxaziridinium salt 4.
Experimental
Melting points (mp) were determined on a Buchi 535 capillary melting apparatus and are not corrected. The 1H NMR (400 MHz) and 13C NMR (100 MHz) spectra were recorded in CDCl3 on a Mercury Plus Varian 400 spectrometer. The low-resolution ESI mass spectrum was acquired on a Thermo Scientific LCQ spectrometer and the high-resolution mass spectrum was obtained using a Thermo Fisher Scientific LTQ FT Ultra spectrometer. IR spectra were determined on a Nicolet NEXUS-470 FT-IR spectrometer in KBr pellets.
Analytical TLC was performed on a Merck precoated TLC (silica gel 60 F254) plate.
5-Methoxy-2-[3,5-dimethyl-4-methoxy-2-pyridyl]methylsulfanyl-1H-benzimidazole (2)
A 500 mL three-necked round bottom flask equipped with an efficient mechanical stirrer was charged with methanol (400 mL), 2-chloromethyl-3,5-dimethyl-4-methoxypyridine hydrochloride (48.6 g, 0.22 mol), 5-methoxybenzimidazol-1H-2-thione (1, 36.0 g, 0.2 mol) and sodium carbonate (46.6 g, 0.44 mol). The mixture was heated under reflux for 1.5 h while the progress of the reaction was monitored by TLC. After completion of the reaction, the mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was dissolved in toluene and the solution was washed with aqueous solution of sodium carbonate and concentrated. The residue was crystallized from toluene to furnish 62.25 g (95%) of 2; purity 99% (HPLC); mp 120.0–121.8°C; 1H NMR: δ 2.26 (s, 3H), 2.30 (s, 3H), 3.76 (s, 3H), 3.82 (s, 3H), 4.38 (s, 3H), 6.79 (m, 1H), 7.03 (d, 1H, J = 2.5), 7.39 (d, 1H, J = 8.5), 8.24 (s, 1H); 13C NMR: δ 165.0, 155.9, 150.8, 148.5, 126.3, 125.5, 114.8, 110.9, 97.5, 60.1, 55.8, 35.2, 13.6, 11.3; MS: m/z 330.2 [M + H]+; IR: v 2958, 1635, 1593, 1456, 1436, 1404, 1344, 1263, 1190, 1155, 1080, 1029, 837, 806, 657cm-1.
(R)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2- pyridinylmethyl)sulfinyl]-1H-benzimidazole (3)
A 1000 mL three-necked round bottom flask equipped with an efficient mechanical stirrer, was charged with dichloromethane (500 mL) and compound 2 (8.22 g, 25 mmol). With stirring, the solution was cooled to -70°C under argon and treated with a solution of salt 4 (16.43 g, 25 mmol) in dichloromethane. The temperature of the mixture was allowed to reach slowly room temperature (about 3 h) before work up. The progress of the reaction was monitored by TLC. After the reaction has completed, the mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography to furnish white crystals of the sulfoxide 3; yield 7.42 g (86%); enantiomeric excess 98%; purity 99.5% (HPLC); mp 154.0–156.0°C; [α]20D +155 (c = 0.5, CHCl3); 1H NMR: δ 2.18 (m, 6H), 3.66 (s, 3H), 3.81 (s, 3H), 4.80 (m, 2H), 6.90 (m, 2H), 7.60 (s, 1H), 8.17 (s, 1H); 13C NMR: δ 164.4, 157.7, 151.2, 149.6, 148.8, 138.2, 135.4, 126.9, 126.4, 120.7, 113.6, 94.6, 60.7, 59.9, 55.7, 13.3, 11.5; HRMS: m/z 346.1225 [M + H]+; IR: v 2937, 1624, 1589, 1566, 1471, 1431, 1396, 1305, 1269, 1205, 1151, 1076, 1026, 810, 621 cm-1.
Acknowledgments
This work was supported by Science and Technology Project of Taizhou (No. 131KY07), Scientific Research Fund of Zhejiang Provincial Education Department (No. Y201329469), the Research Foundation for Post-doctoral Scientists of Taizhou (No. 2013BSH01) and the Program for Changjiang Scholars and Innovative Research Team in Chinese University (No. IRT 1231).
References
[1] Venkata Subbaiah, B.; Sree Ganesh, K. K.; Prakash, L.; Subramanyam Reddy, K. Preparative isolation and UPLC-TOF MS identification of eight degradants from stressed tablets of esomeprazole. J. Liq. Chromatogr. Relat. Technol. 2013, 36, 1243–1250.10.1080/10826076.2012.685921Search in Google Scholar
[2] Federsel, H. J.; Larsson, M. In Asymmetric Catalysis on Industrial Scale. , H.-U., Schmidt, E., Eds. Wiley-VCH, Weinheim, 2004, p 413.10.1002/3527602151.ch24Search in Google Scholar
[3] Cotton, H.; Elebring, T.; Larsson, M.; Li, L.; Soensen, H.; Unge, S. V. Asymmetric synthesis of esomeprazole. Tetrahedron: Asymmetry2000, 11, 3819–3825.10.1016/S0957-4166(00)00352-9Search in Google Scholar
[4] Federsel, H. J. Asymmetry on large scale. The roadmap to the stereoselective processes. Nat. Rev. Drug Discovery2005, 4, 685–697.10.1038/nrd1798Search in Google Scholar PubMed
[5] Federsel, H. J. In search of sustainability. Process R&D in light of current pharmaceutical industry challenges. Drug Discov. Today2006, 11, 966–974.10.1016/j.drudis.2006.09.012Search in Google Scholar PubMed
[6] Pitchen, P.; Kagan, H. B. An efficient asymmetric oxidation of sulfides to sulfoxiues. Tetrahedron Lett. 1984, 25, 1049–1052.10.1016/S0040-4039(01)80097-6Search in Google Scholar
[7] Di Furia, S. H.; Modena, G.; Seraglia, G. Synthesis of chiral sulfoxides by metal-catalyzed oxidation with t-butyl hydroperoxide. Synthesis1984, 1984, 325–326.10.1055/s-1984-30829Search in Google Scholar
[8] Liu, X. P.; Xu, H. L.; Sun, R.; Li, X.; Hu, B. H.; Hu, C. Synthesis and characterization of two impurities in esomeprazole, an antiulcerative drug. Lat. Am. J. Pharm. 2015, 34, 1265–1268.Search in Google Scholar
[9] Toribio, L.; Alonso, C.; del Nozal, M. J.; Bernal, J. L.; Martín, M. T. Semipreparative enantiomeric separation of omeprazole by supercritical fluid chromatography. J. Chromatogr. A2006, 1137, 30–35.10.1016/j.chroma.2006.09.092Search in Google Scholar
[10] Olsson, J.; Stegander, F.; Marlin, N.; Wan, H.; Blomberg, Lars G. Enantiomeric separation of omeprazole and its metabolite 5-hydroxyomeprazole using non-aqueous capillary electrophoresis. J. Chromatogr. A2006, 1129, 291–295.10.1016/j.chroma.2006.07.001Search in Google Scholar
[11] Von Unge, S.; Fregler, C. New compounds useful for the synthesis of S-and R-omeprazole and a process for their preparation. US 2005/0187256A1, 2005.Search in Google Scholar
[12] Von Unge, S. A process for the opical purification of enantiomerically enriched benzimidazole derivatives. WO 97/02261, 1997.Search in Google Scholar
[13] Del Rio, R. E.; Wang, B.; Achab, S.; Bohe, L. Highly enantioselective oxidation of sulfides to sulfoxides by a new oxaziridinium salt. Org. Lett. 2007, 9, 2265–2268.10.1021/ol0702573Search in Google Scholar
[14] Song, W. G.; Dong, L. J.; Zhou, Y. H.; Fu, Y. Q.; Xu, W. F. Catalytic asymmetric synthesis of esomeprazole by a Titanium complex with a hexa-aza-triphenolic macrocycle ligand. Synthetic Commun. 2015, 45, 70–77.10.1080/00397911.2014.952307Search in Google Scholar
[15] Reguri, B. R.; Upparapalli, S.; Sivadas, A.; Vigneswara Chellam, R.; Shamuga Sundaram,B. K.; Subbaiah, R. An inproved process for the preparation of esomeprazole magnesium dihydrate. WO 2003/097614 A2, 2011.Search in Google Scholar
©2016 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Preliminary Communication
- Design, synthesis, and anticancer activity of novel aryl/heteroaryl chalcone derivatives
- Research Articles
- A simple and convenient method for the synthesis of 1,3,5-triazine-nitrolic acids. The first X-ray investigation of Z-isomeric nitrolic acid
- Pot, atom and step-economic (PASE) synthesis of medicinally relevant spiro[oxindole-3,4′-pyrano[4,3-b]pyran] scaffold
- An efficient asymmetric approach to the R-enantiomer impurity of esomeprazole
- Synthesis, optical and electrochemical properties of 2-[(9H-fluoren-2-yl)aryl]-1H-benz[d]imidazole and 2,7-bis[(1H-benz[d]imidazol-2-yl)aryl]- 9H-fluorene derivatives
- Synthesis and fluorescence of pyrazolines substituted with pyrimidine and ferrocene subunits
- Design and synthesis of a novel rhodamine-based chemosensor and recognition study to Fe3+
- An efficient, one-pot three-component synthesis of 4H-thiazolo[3,2-a][1,3,5]triazin-6-one derivatives
- Microwave-assisted synthesis and antibacterial evaluation of new derivatives of 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
- Efficient assembly of quinoxaline derivatives from benzene-1,2-diamines, dialkyl acetylenedicarboxylates and ninhydrin
Articles in the same Issue
- Frontmatter
- Preliminary Communication
- Design, synthesis, and anticancer activity of novel aryl/heteroaryl chalcone derivatives
- Research Articles
- A simple and convenient method for the synthesis of 1,3,5-triazine-nitrolic acids. The first X-ray investigation of Z-isomeric nitrolic acid
- Pot, atom and step-economic (PASE) synthesis of medicinally relevant spiro[oxindole-3,4′-pyrano[4,3-b]pyran] scaffold
- An efficient asymmetric approach to the R-enantiomer impurity of esomeprazole
- Synthesis, optical and electrochemical properties of 2-[(9H-fluoren-2-yl)aryl]-1H-benz[d]imidazole and 2,7-bis[(1H-benz[d]imidazol-2-yl)aryl]- 9H-fluorene derivatives
- Synthesis and fluorescence of pyrazolines substituted with pyrimidine and ferrocene subunits
- Design and synthesis of a novel rhodamine-based chemosensor and recognition study to Fe3+
- An efficient, one-pot three-component synthesis of 4H-thiazolo[3,2-a][1,3,5]triazin-6-one derivatives
- Microwave-assisted synthesis and antibacterial evaluation of new derivatives of 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
- Efficient assembly of quinoxaline derivatives from benzene-1,2-diamines, dialkyl acetylenedicarboxylates and ninhydrin